Tallac Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
866 Malcolm Rd Ste 100, Burlingame, Cali...Phone Number
(650) 866-1966Website
www.tallactherapeutics.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Tallac Therapeutics
Based out of Burlingame, CA, Tallac Therapeutics is a privately held biopharmaceutical company with a focus on cancer immunities.Explore more
Tallac Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tallac Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Tallac Therapeutics is spiking on competitors!
Product Launch: Get notified when Tallac Therapeutics launches new products
Check if Tallac Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Tallac Therapeutics recently announced quarterly report
Click to see if Tallac Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Tallac Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Tallac Therapeutics
Funding: Get notified immidiatlly once Tallac Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Tallac Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Tallac Therapeutics
Compare insights from companies similar to Tallac Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tallac Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tallac Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tallac Therapeutics.
Tallac Therapeutics financials insights
Gather financial insights about Tallac Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$62M
Tallac Therapeutics Tech Stack
A closer look at the technologies used by Tallac Therapeutics
See more technologies
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Tallac Therapeutics News & Media
Tallac Presents First Clinical Data for TAC-001 at SITC 2023
BURLINGAME, Calif.--(BUSINESS WIRE)--Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the first presentation of TAC-001 Phase 1 clinical safety and efficacy data in solid tumor patients. TAC-001 is an investigational, systemically delivered, TRAAC molecule comprised of a potent TLR9 Agonist conjugated to a CD22 antibody, designed to selectively activate B cells to drive an anti-tumor immunTallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
BURLINGAME, Calif.--(BUSINESS WIRE)--Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the acceptance of two abstracts (related to TAC-001 and TAC-003) at the SITC 38th Annual Meeting in San Diego, CA, from November 3-5, 2023. Additionally, Tallac announced that President and CEO, Hong Wan and Chief Business Officer, Curtis Hecht will participate and host investor meetings at the Truist SecTallac Therapeutics Receives $15M Venture Loan Facility
Tallac Therapeutics, Inc., a Burlingame, CA-based developer of multiple novel immunotherapies to fight cancer, received a $15m venture loan facility. Horizon Technology Finance Corporation (NASDAQ: HRZN) provided the financing. A sum of $5m has been initially funded. The company will use the loan proceeds for general growth and working capital purposes. Led by Hong I. Wan, Ph.D., president, […] The post Tallac Therapeutics Receives $15M Venture Loan Facility appeared first on FinSMEs.Horizon Technology Finance Provides $15 Million Venture Loan Facility to Tallac Therapeutics
FARMINGTON, Conn., Aug. 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tallac Therapeutics
Sign Up For FreeTo access detailed company insights
Based out of Burlingame, CA, Tallac Therapeutics is a privately held biopharmaceutical company with a focus on cancer immunities.... Read More
